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Abstract
Background: Although the majority of solitary fibrous tumors of the pleura (SFTP) follow a benign course, 10–25%
of patients suffer from recurrence or metastatic disease. Several scoring models have been proposed to predict the
outcome. However, none of these included immunohistochemical (IHC) markers as possible prognosticators.
Methods: In this multicenter study, we collected clinical data and formalin-fixed and paraffin-embedded (FFPE) tissue
blocks of patients with histologically proven SFTP which had been surgically resected between 2000 und 2015. After
systematic and extensive IHC staining on tissue microarrays, the results were analyzed and compared to
histomorphological and clinical data for their possible prognostic value.
Results: In total, 78 patients (mean age 61 ± 11 years) were included. Of these, 9 patients (11%) had an adverse outcome
including SFTP recurrence (n= 6) or SFTP-related death (n= 3). Mean overall survival was 172 ± 13 months. 1 and 10-year
event-free survival rates were 99% and 93%. In the multivariable analysis only MIB-1 proliferation index (Ki-67) ≥10% (HR 12.
3, CI 1.1–139.5, p= 0.043), ≥4 mitoses per 10 high power fields (HR 36.5, CI 1.2–1103.7, p= 0.039) and tumor size larger than
10 cm (HR 81.8, CI 1.7–4016.8, p= 0.027) were independently associated with adverse outcome.
Conclusion: A high proliferation rate by MIB-1 IHC was associated with impaired outcome. Upon this, we established a
new score using mitosis, necrosis, size of the tumor and MIB-1, which performed better than the traditional scores in our
data set. This prognostic score could help to better evaluate outcome of SFTP, but requires external validation.
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Background
Solitary fibrous tumors of the pleura (SFTP) are rare
neoplasms of the chest cavity with an estimated inci-
dence of 2.8 new cases/100,000 individuals/year [1, 2].
They are responsible for less than 5 % of all tumors aris-
ing from the pleura, but have been reported to occur in
other anatomical locations [3–5]. Klemperer et al. were
the first to describe SFTP in 1931, and since then only
900 cases have been reported up to 2005 [1, 6].
According to their distinct histological pattern, SFTP
used to be called ‘hemiangiopericytoma’. A variety of
other names were used, which made it difficult to clas-
sify them into one entity [7]. Histologically, they typically
show alternate areas with varying hypercellularity.
Characteristic in those less cellular areas is a dense
collagenous background with variable assembled spin-
dle cells, the so-called “patternless pattern” and
haemangiopericytoma-like branching blood vessels. By
using immunohistochemical (IHC) staining including
CD34 and CD99, it has been shown that SFTP seem
to originate from mesenchymal tissue [8, 9]. However,
the major breakthrough in the firm diagnosis of SFTP
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was the detection of the NAB-STAT6 gene fusion
which is present in up to 100% of these tumors and,
thus, has been shown to help diagnosing these rare
neoplasms and distinguish them from histologic
mimics [10–12]. Furthermore, some studies suggested
that a certain fusion type might be associated with
different variations of SFTP [13, 14].
The majority of SFTP seem to follow a benign behav-
ior. However, 10–25% can relapse or present signs of
malignancy, i.e. metastases [15]. In 1989, England et al.
proposed morphological and histological characteristics
to distinguish malignant from benign variants of SFTP
[16]. These included tumor size, atypical localization,
sessile rather than pedunculated tumor, necrosis or
hemorrhage, more than four mitoses per 10 high power
fields (HPF), and nuclear pleomorphism. These features
built the basis for subsequent scoring systems which
have been introduced to better predict the biological be-
havior of SFTP [17, 18]. However, these scoring systems
do not consider IHC markers as possible prognosticators
of the biological behavior. The aim of this study was to
investigate the role of clinical, morphological and, in
particular, IHC staining as possible prognosticator of the
outcome in patients with SFTP.
Methods
Subjects and data
Patients were recruited at seven hospitals in Switzerland
and Germany. All patients with a histologically proven
SFTP who were diagnosed and operated between 2000
and 2015 at one of these centers and had a follow-up of
at least one month were eligible for the study. Patients’
clinical and follow-up data were drawn from the medical
records and, if required, obtained from their general
practitioners.
Formalin-fixed and paraffin-embedded (FFPE) tissue
blocks and representative slides of every eligible patient
were collected from all participating hospitals. Accuracy
of the SFTP diagnosis was achieved using IHC for
STAT6 c-terminus epitope as a surrogate marker for the
NAB-STAT6 fusion protein which was performed in
every sample. All NAB-STAT6 negative tumors were
microscopically re-examined by an expert lung patholo-
gist (A.S.). Patients with incorrect diagnosis of SFTP or
missing FFPE tissue block were excluded from the study.
Written informed consent was obtained from all pa-
tients or their relatives. The study was approved by the
Ethics committee of the Canton of Zurich (KEK-ZH
2012–0279), and the study was notified at Clinical-
Trials.gov (Identifier: NCT01694654).
Hybrid cytology/tissue microarray
To reproduce a representative profile of the whole tumor
we obtained four cores for every patient and selected two
less proliferative and two more proliferative areas of the
parrafin block. From each of these regions of the donor
block, a paraffin core of 0.6 mm diameter and 3–4 mm
height was taken and precisely arrayed into a new recipi-
ent paraffin block using a custom-made, semiautomatic
tissue arrayer (taucherinsel-neuenburg@t-online.de). Of
these, 2.5 μm sections were cut for IHC staining which
was performed under standardized conditions. Commer-
cially available antibodies were used for IHC staining. The
following antibodies were used: MIB-1 (Rabbit anti-Ki-67,
mib 1, clone 30–9, Ventana-Roche, Tucson, AZ, USA),
CD 34 (Confirm anti-CD34, clone QBEnd/10, Ventana-
Roche, Tucson, AZ, USA), bcl-2 (Mouse anti-bcl-2, clone
124 Ventana-Roche, Tucson, AZ, USA), CD99 (Mouse
anti-human CD99, clone HO36–1.1, Novocastra labora-
tories Ltd., Newcastle upon Tyne, UK), p53 (Mouse anti-
human p53 Protein, clone DO-7, DAKO A/S, Glostrup,
Denmark), Vimentin (Mouse anti-human Vimentin, clone
VIM3B4, DAKO A/S, Glostrup, Denmark), Insulin-like-
growth-factor IGF2 (Mouse anti-Insulin like growth
factor 2, Cell Signaling Technology, Cambridge, UK)
and NAB- STAT-6 (Stat6 S-20, Santa Cruz Biotech-
nology Inc., Dallas, TX, USA).
Immunohistochemistry
Immunoreactivity of the samples was scored visually by
M.D. and a dedicated pathology technician. The staining
of all IHC markers except MIB-1 were semi-quantitatively
scored from 0 (negative) to 3 (strong reaction) in all four
cores. Finally, the mean of these scores was used for
statistical analysis. For MIB-1 proliferation index, all
the cells were counted visually and the percentage of
cells having any positivity was calculated. The mean
percentage of positive cells of all four cores was used
for statistical analysis.
Definition of adverse outcome
Adverse outcome was defined as recurrence of SFTP, de-
velopment of metastases or SFTP-related death. Thus,
event-free survival time was defined as the time between
surgery and the occurrence of an adverse outcome.
Statistical analysis
All statistical analyses were performed using SPSS Statis-
tics for Windows, version 20.0 (IBM Corporation,
Armonk, NY). χ2-test (categorical data) and Mann-
Whitney U test (continuous data) were used to deter-
mine a significant association between the variables and
an adverse outcome. Overall-survival and event-free sur-
vival were calculated using Kaplan-Meier curves. To es-
timate a prognostic value of each variable we used the
Cox regression model. Each variable with a p-value less
than 0.1 was entered in a multivariable analysis, and the
hazard ratio (HR) and confidence interval (CI) were
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computed. A p-value less than 0.05 was considered to be
significant. We tested morphological, clinical and IHC
staining variables for their possible prognostic value.
Furthermore, sensitivity and specificity of the currently
used scores were computed.
Results
Demographics and clinical presentation
From 109 eligible patients, a total of 78 patients (41%
males, mean age 61 ± 11 years) were included in the
study (Fig. 1). Twenty-five patients (32%) were active or
former smokers. At the time of diagnosis 27 patients
(35%) reported symptoms such as dyspnea (19%) and
chest pain (13%). Symptomatic hypoglycemia was found
in 3 patients (7%). In 32 cases SFTP was an incidental
finding (41%).
Therapy
All patients were treated surgically. SFTP were re-
moved by video-assisted thoracoscopy (50%) or thora-
cotomy (50%), performing a wedge resection (82%) a
lobectomy (12%) or a pneumonectomy (6%). Peri-
operative complications were reported in a total of 11
cases (14%) including bleeding (n = 1), hydrothorax (n = 1),
prolonged air leak (n = 3), allergic reaction (n = 1),
intercostal neuralgia (n = 1) and sepsis (n = 1). 30-day
mortality was 0%. The median length of hospital stay
was 6 (range 3–25) days.
Fig. 1 Study flowchart. SFT(P), solitary fibrous tumor (of the pleura)
Table 1 Histomorphological features of solitary fibrous tumors of the pleura
Characteristics All (n = 78) Adverse outcome (n = 9) Favorable outcome (n = 69) p-value*
Atypical location (parietal), n (%) 15 (19.2) 1 (12.5) 14 (20.3) 0.5
Tumor size, median (IQR) 8.2 (4.05–14.0) 17.0 (9.1–21.5) 6.3 (3.9–12.6) 0.007
Tumor size >10 cm, n (%) 31 (39.7) 7 (77.8) 24 (35.3) 0.019
Non-pedunculated, n (%) 14 (31.8) 2 (66.7) 12 (29.3) 0.2
Necrosis, n (%) 22 (28.6) 5 (62.5) 17 (24.6) 0.039
Hemorrhage, n (%) 17 (22.1) 3 (37.5) 14 (20.3) 0.4
Mitotic count, median (IQR) 1 (1.0–3.75) 7 (3–15) 1 (1–3) 0.005
> 4 mitoses / 10 HPF, n (%) 16 (25) 5 (71.4) 11 (19.3) 0.009
Pleomorphism, n (%) 8 (10.4) 3 (37.5) 5 (7.2) 0.033
Hypercellularity 19 (57.6) 7 (87.5) 12 (48) 0.056
HPF high power field, IQR interquatile range
*Chi-square test or Mann-Whitney U-test as appropriate
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Event-free survival and adverse outcome
The mean overall survival after surgery was 172 ±
13 months. The mean event-free survival was 165 (±15)
months with a median follow-up time of 36 months
(range 1–216). After one and ten years, the event-free sur-
vival rates were 99% and 93%, respectively. Nine patients
(11%) had an adverse outcome including SFTP recurrence
(n = 6, 7.7%) and SFTP-related death (n = 3, 0.04%). No
patient developed metastases. Another five patients died
of unrelated causes during follow-up time.
Conventional prognosticators of adverse outcome
The classical histomorphological characteristics pro-
posed by England et al. [16] and Tapias et al. [17] are
summarized in Table 1. Three of the conventional
England et al. [16] features were associated with adverse
outcome (Table 3). In multivariable analysis, only tumor
size ≥10 cm and ≥ four mitoses/10 HPF were independ-
ently associated with adverse outcome. All the other his-
tomorphological variables including presence of necrosis
or hemorrhage, atypical location and sessile morphology
were not significant. Sensitivity and specificity for the
diagnosis of a malignant SFTP variant was 89% (95% CI
51.8–99.7) and 59% (95% CI 47–71), respectively, when
using the characteristics by England et al. [16] (HR 18.8,
95% CI 2.2–160.6, p = 0.007). When applying the criteria
by de Perrot et al. [18] in our cohort, the distribution of
tumor stages was as follows: 17 patients stage 0 (21.3%),
6 patients stage I (7.7%), 13 patients stage II (16.7%), 8
patients stage III (10.3%) and 0 patients stage IV. Due to
missing data we could not perform the score in the
remaining 34 patients (43.6%). Sensitivity and Specificity
for the diagnosis of a malignant SFTP variant was 100%
(95% CI 29.2–100) and 56% (95% CI 39.8–71.5), respect-
ively. Stage II and Stage III tumors were not associated
with adverse outcome (HR 79.6, 95% CI 0.007–920,630,
p = 0.359). The recently introduced score by Tapias et al.
[17] which has been proposed to predict the risk of re-
currence did not show a significant association between
a score greater than three points and recurrence (HR
777.8, 95% CI 0.1–164,317,352, p = 0.287). However, sen-
sitivity and specificity of the Tapias score for prediction
of recurrence was 100% (95% CI 48–100%) and 76%
(95%CI 65–86%), respectively.
Immunohistochemical markers as possible
prognosticators of adverse outcome
The IHC staining profile of SFTP is displayed in Table 2.
For MIB-1 proliferation index scores ranged from 0 to
50% with a median of 1 (IQR 1–3). When comparing
the HRs and p-values of MIB-1 proliferation index in
univariable analysis a cut-off value of 10% performed
best to predict adverse outcome. In the univariable
Table 2 Immunohistochemical staining profile of solitary fibrous
tumors of the pleura
Staining All (n = 78) Adverse
outcome
(n = 9)
Favorable
outcome
(n = 69)
p-value*
CD34, n (%) 0.6
0 0 (0) 0 (0) 0 (0)
1 11 (14.1) 2 (22.2) 9 (13.0)
2 27 (34.6) 2 (22.2) 25 (36.2)
3 40 (51.3) 5 (55.6) 35 (50.7)
Bcl-2, n (%) 0.2
0 0 (0) 0 (0) 0 (0)
1 25 (32.1) 3 (33.3) 22 (31.9)
2 27 (34.6) 1 (11.1) 26 (37.7)
3 26 (33.3) 5 (55.6) 21 (30.4)
Vimentin, n (%) n/a
0 0 (0)
1 0 (0)
2 0 (0)
3 78 (100)
NAB-STAT6, n (%) 0.86
0 3 (3.8) 2 (22.2) 1 (1.4)
1 24 (30.8) 1 (11.1) 23 (33.3)
2 35 (44.9) 3 (33.3) 32 (46.4)
3 16 (20.5) 3 (33.3) 13 (18.8)
p53, n (%) 0.13
0 3 (3.9) 0 (0) 3 (4.5)
1 40 (52.6) 4 (44.4) 36 (53.7)
2 28 (36.8) 2 (22.2) 26 (38.8)
3 5 (6.6) 3 (33.3) 2 (3)
IGF2, n (%) n/a
0 0 (0)
1 0 (0)
2 0 (0)
3 78 (100)
CD99, n (%) 0.6
0 4 (5.1) 1 (11.1) 3 (4.3)
1 39 (50.0) 5 (55.6) 34 (49.3)
2 22 (28.2) 1 (11.1) 21 (30.4)
3 13 (16.7) 2 (22.2) 11 (15.9)
MIB-1 proliferation index
(Ki-67), median % (IQR)
1 (1.0–3.0) 10 (1–17) 1.0 (1.0–2.5) 0.044
MIB-1 proliferation index
(Ki-67)≥ 10%, n (%)
5 (6.4) 5 (55.6) 0 (0) < 0.001
The stainings were classified as negative (0), weak (1), intermediate (2)
and strong (3)
HPF high-power field, n/a not applicable
*Chi-square test or Mann-Whitney U-test as appropriate
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analysis, only MIB-1 proliferation index (Ki-67) ≥10%
was significantly associated with adverse outcome.
MIB-1 proliferation index remained significant in mul-
tivariable analysis (HR 13.3, CI 3.5–50.7, p = 0.043)
(Table 3). Kaplan-Meier survival curve according to
MIB-1 proliferation index is shown in Fig. 2.
Proposal of a new scoring system
On the basis of the above data, we established a new
scoring system containing four variables, attributing to
one point for each variable if it was above a specific
threshold (Table 4). If a variable was missing, it was as-
sumed to be less than the threshold and assigned a point
value of 0. For the proposed scoring system, we included
all three variables, which remained significant in the
multivariable analysis in addition to presence of necrosis,
which is one well-validated risk criteria as shown in
Table 4.34 patients had a score of 0 (43.6%), 24 patients
a score of 1 (30.8%), 12 patients a score of 2 (15.3%), 6
patients a score of 3 (7.7%) and two patients had a score
of 4 (2.6%). When using a score of two or more point,
the score performed best and was significantly asso-
ciated with adverse outcome (HR 32.9, CI 4.0–270.9,
p = 0.001). Kaplan-Meier survival curve according to
the new score is shown in Fig. 3. Sensitivity and spe-
cificity was 89% (95% CI 52–100%) and 83% (95%CI
72–91%), respectively.
Discussion
In this multicenter study, we collected clinical data and
FFPE tissue blocks of patients with histologically proven
SFTP, aiming to investigate IHC markers which may im-
prove predicting the biological behavior of SFTP. Eleven
percent of patients had an adverse outcome. SFTP-
related lethality was 0.04%, whereas recurrence rate was
7.7% compared to 10–25% in other series [15, 16, 18].
This could be related to a shorter follow-up time in our
study with a median follow-up time of 36 months com-
pared to a median follow-up time of 70 months in the
study of Schirosi et al. [15].
While the majority of SFTP follow a benign course,
few SFTP will behave aggressively and lead to recur-
rence, tumor-related death or metastatic disease. How-
ever, many SFTP originally classified as malignant follow
a benign course, and vice-versa [16, 19]. Therefore,
England et al. proposed six histomorphological features
to characterize malignant variants [16]. These features
are widely accepted and used in many centers. It is not
clearly defined though, which and how many of these
features have to be fulfilled to define a malignant variant
of SFTP. In our study, from the variables included in the
criteria proposed by England et al., [16] only tumor size
greater than 10 cm, nuclear pleomorphism and in-
creased mitotic activity (more than four mitoses per 10
HPF) were significantly associated with an adverse out-
come in univariable analysis. Yet, in the multivariable
analysis, only two of these features (mitotic count and
tumor diameter) remained significant. This finding was
already confirmed by other studies demonstrating that
only mitotic count and tumor size were associated with
impaired outcome [20, 21]. Furthermore, the specificity
of the England criteria was challenged by Schirosi et al.
who showed that at least one of these variables is
present in 59% of SFTP, whereas mortality and recur-
rence rate are only 10% and 18%, respectively [15].
Recently new scoring systems have been proposed
to predict either the risk of recurrence or the com-
bined risk of adverse outcome, namely recurrence,
development of metastasis or SFTP-related death
[17, 18]. De Perrot et al. proposed a model based on
morphologic and histologic features (morphology,
high cellularity, cellular pleomorphism, high mitotic
count, necrosis or stromal/vascular invasion) with a
treatment plan and recommendation of adjuvant
therapy and follow up [18]. Likewise, Tapias et al.
suggested a scoring system to predict the risk of
recurrence based on certain histologic and morpho-
logic features (pleural origin, morphology, size,
hypercellularity, presence of necrosis or haemor-
rhage, number of mitosis per 10 HPFs) [17]. How-
ever, we could not confirm those scores proposed by
Table 3 Univariable and multivariable analysis of possible predictors of the biological behavior of solitary fibrous tumors of the pleura
Variable Univariable analysis Multivariable analysis
HR (95% CI) p-value HR (95% CI) p-value
Tumor size ≥10 cm 8.8 (1.8–43.5) 0.008 81.8 (1.7–4016.8) 0.027
Necrosis 3.4 (0.8–14.6) 0.089 1.7 (0.1–18.4) 0.7
MIB-1≥ 10% 13.3 (3.6–50.7) < 0.001 12.3 (1.1–139.5) 0.043
Mitoses ≥4/10 HPF 13.1 (1.6–112.0) 0.019 36.6 (1.2–1103.7) 0.039
Atypical location 1.6 (0.2–13.4) 0.641
Non-pedunculated 196.6 (0.0–126,601,532.0) 0.439
Pleomorphism 9.8 (2.2–44.5) 0.003 11.2 (0.6–22.3) 0.1
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Tapias et al. [17] in our cohort, since it was not as-
sociated with the risk of recurrence or adverse
outcome.
In the end, none of the grading systems based on his-
tomorphological features is sufficiently accurate to pre-
dict the biological behavior of SFTP at the time of
diagnosis. Thus, attempts to find new biomarkers or to
expand the conventional grading systems by new
biomarkers is warranted. However, none of the above
mentioned studies investigated the prognostic value of
IHC markers. A reason for this could be that IHC stain-
ing for SFTP is not standardized and, thus, not uni-
formly used in different centers. Likewise, MIB-1
proliferation index (Ki-67) has not been routinely mea-
sured, although some studies showed a trend towards a
promising prognostic value of MIB-1 [17, 20, 22]. We
collected FFPE tissue blocks of patients with histologi-
cally proven SFTP from seven hospitals in two countries
and uniformly performed IHC staining on them. Loss of
CD34 expression has been shown to be more prevalent
in malignant SFTP [23]. We could not confirm this find-
ing, since all SFTP in our study were positive for CD34.
Furthermore, positivity of the tumor suppressor protein
p53 has been shown to be associated with malignant fea-
tures [15, 23]. In our study, p53 expression was not sig-
nificantly more prevalent in patients with adverse
outcome. NAB-STAT6 gene fusion has been shown to
be present in the vast majority of SFTP and is used for
diagnosis of these tumors with a sensitivity and specifi-
city of 98% and 85%, respectively [10–12, 24]. In our
study only three SFTP showed negativity for NAB-
STAT6 resulting in a sensitivity of 96% in diagnosing
SFTP, which is similar to other published series [10, 11].
MIB-1 is an antibody against Ki-67 which is a protein
associated with cell proliferation and ribosomal RNA
synthesis. Thus, MIB-1 is a reliable IHC marker of cell
proliferation, and MIB-1 proliferations index (Ki-67 ex-
pression) is associated with poor prognosis in various
cancers, especially breast and prostate cancer [25, 26].
However, the prognostic value of MIB-1 proliferation
Fig. 2 Kaplan-Meier survival curve according to MIB-1 proliferation index (Ki-67)
Table 4 Proposal of a new scoring system for solitary fibrous
tumors of the pleura
Variables Points
Mitoses ≥4/10 HPF 1
Mitoses <4/10 HPF (or Mitoses missing) 0
Tumor size ≥10 cm 1
Tumor size <10 cm (or tumor size missing) 0
MIB-1≥ 10% 1
MIB-1 < 10% (or MIB-1 missing) 0
Necrosis 1
No Necrosis (or necrosis missing) 0
Score interpretation: Each variable scoring a point with a maximum of four points
and a minimum of zero points. A missing variable was computed as a value of 0
A score of ≥1 point was associated with adverse outcome with a sensitivity of
88% (95% CI 52–100%) and a specificity of 48% (95% CI 36–60%). (HR 7.03, CI
0.87–56.69, p = 0.067)
A score of ≥2 points was associated with adverse outcome with a sensitivity of
89% (95% CI 52–100%) and a specificity of 83% (95% CI 72–91%). (HR 32.9, CI
4.0–270.9, p = 0.001)
A score of ≥3 points was associated with adverse outcome with a sensitivity of
33% (95% CI 7–70%) and a specificity of 94% (95% CI 86–98%). (HR 4.6, CI
1.2–18.5, p = 0.031)
A score of 4 points was associated with adverse outcome with a sensitivity of
22% (95% CI 3–60%) and a specificity of 100% (95% CI 95–100%). (HR 102.03,
CI 8.97–1160.95, p < 0.001)
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index has not yet been systematically investigated in
SFTP. To date, there is only one retrospective study in a
relatively small cohort published by our group, revealing
that a high proliferation index assessed with Ki-67 was
associated with poor prognosis [20]. To the best of our
knowledge, the present study is the largest to systematic-
ally investigate the role of MIB-1 in SFTP. We found
that a high proliferation index MIB-1 of more than 10%
was independently associated with adverse outcome.
Upon this finding, we established a new score using
the variables which have been shown to correlate with
impaired outcome. This score, using mitosis count,
tumor size, MIB-1 and necrosis performed better than
traditional scores in predicting adverse outcome of SFTP
in our cohort. Compared to the criteria proposed by
England et al. [16] or the score proposed by Tapias et al.
[17] this score is the first to use an IHC marker. We ex-
cluded histomorphological features, such as pleomorph-
ism, nuclear atypia and hemorrhage, since they are
subject to inter-observer variability and lack clear-cut
objectiveness. Certainly, this score has to be validated in
a larger population, but, nevertheless we highly recom-
mend including MIB-1 in any future score.
A clear strength of our study is a considerably high pa-
tient number drawn from multiple centers despite the
low incidence of SFTP. Furthermore, the design of the
study allowed a systematical and uniform investigation
of IHC staining and their prognostic value. However,
some limitations merit consideration. First, there was a
relatively short follow-up time. Secondly, due to lack of
variety of proliferation rates we could not perform a re-
ceiver operating curve (ROC) analysis to evaluate the
best cut-off value of MIB-1. Finally, considering the
histological structure of SFTP with alternate areas of
more or less proliferation, it has to be further evaluated,
whether our scoring of MIB-1 using two less and two
more proliferative areas is reproducible in other series.
Conclusion
In addition to tumor diameter and mitotic count, MIB-1
proliferation index is a significant prognosticator of ad-
verse outcome in patients with SFTP. A prognostic score
including these three features and necrosis performed
better than the traditional scores only based on histo-
morphological criteria. Validation of this score is recom-
mended in a future study with longer follow-up time.
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